Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Barsouk

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
JTO Clinical and Research Reports|August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLCOmar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 17, 2021
Glioblastoma with deep supratentorial extension is associated with a worse overall survivalAdam Barsouk, Michael P Baldassari, Omaditya Khanna, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinibAdam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
Operative Neurosurgery (Hagerstown, Md.)|May 11, 2023
Clinical Outcomes After Ultra-Early Cranioplasty Using Craniectomy Contour Classification as a Patient Selection CriterionPious D Patel, Omaditya Khanna, M Reid Gooch, et al.
Clinical Lung Cancer|January 9, 2024
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab ConsolidationAdam Barsouk, Cole Friedes, Michelle Iocolano, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysisAdam Barsouk, Omar Elghawy, Alex Watts, et al.
Blood|March 18, 2025
STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALLJason Xu, Jonathan H Sussman, Austin Yang, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
JTO Clinical and Research Reports|August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLCOmar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 17, 2021
Glioblastoma with deep supratentorial extension is associated with a worse overall survivalAdam Barsouk, Michael P Baldassari, Omaditya Khanna, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinibAdam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
Operative Neurosurgery (Hagerstown, Md.)|May 11, 2023
Clinical Outcomes After Ultra-Early Cranioplasty Using Craniectomy Contour Classification as a Patient Selection CriterionPious D Patel, Omaditya Khanna, M Reid Gooch, et al.
Clinical Lung Cancer|January 9, 2024
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab ConsolidationAdam Barsouk, Cole Friedes, Michelle Iocolano, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysisAdam Barsouk, Omar Elghawy, Alex Watts, et al.
Blood|March 18, 2025
STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALLJason Xu, Jonathan H Sussman, Austin Yang, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Pageof 4